Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis.
about
The Cure Rate after Placebo or No Therapy in American Cutaneous Leishmaniasis: A Systematic Review and Meta-AnalysisMucosal leishmaniasis: an underestimated presentation of a neglected diseaseDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Easy identification of leishmania species by mass spectrometryLow versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil.Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update.An update on pharmacotherapy for leishmaniasisSpecies typing in dermal leishmaniasisAn Innovative Field-Applicable Molecular Test to Diagnose Cutaneous Leishmania Viannia spp. Infections.Quantitative Kinetoplast DNA Assessment During Treatment of Mucosal Leishmaniasis as a Potential Biomarker of Outcome: A Pilot Study.Cutaneous leishmaniasis with atypical clinical manifestations: Case report.Intralesional Pentamidine: A Novel Therapy for Single Lesions of Bolivian Cutaneous LeishmaniasisIntralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centreComparison of Leishmania typing results obtained from 16 European clinical laboratories in 2014.Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.Parasitic diseases in travelers: a focus on therapy.LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014.Intermediate cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis successfully treated with fluconazole.Cutaneous leishmaniasis in travellers: a focus on epidemiology and treatment in 2015.Identification of Leishmania by Matrix-Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) Mass Spectrometry Using a Free Web-Based Application and a Dedicated Mass-Spectral Library.Miltefosine for Mucosal and Complicated Cutaneous Old World Leishmaniasis: A Case Series and Review of the Literature.Misdiagnosis of cutaneous leishmaniasis and recurrence after surgical excision.Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment.Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis.Two cases of cutaneous leishmaniasis in Dutch military personnel treated with oral miltefosine.Local Delivery of the Toll-Like Receptor 9 Ligand CpG Downregulates Host Immune and Inflammatory Responses, Ameliorating Established Leishmania (Viannia) panamensis Chronic Infection.Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.Efficacy of cryotherapy plus topical Juniperus excelsa M. Bieb cream versus cryotherapy plus placebo in the treatment of Old World cutaneous leishmaniasis: A triple-blind randomized controlled clinical trial.Topical paromomycin and gentamicin for new world cutaneous leishmaniasis in Panama.Travelers with cutaneous leishmaniasis cured without systemic therapy.Interventions for Old World cutaneous leishmaniasis.Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013)Clinical and diagnostic aspects of feline cutaneous leishmaniosis in Venezuela.Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial.
P2860
Q26764752-C90D1909-71D6-4C9D-92B6-7F375AFBCA26Q26998036-9E646A24-C96E-4F35-9253-3BA2FD110809Q30275257-E21D44C2-7977-4DF6-A559-5456024A00BBQ33716734-4686C745-7C38-4C46-B3F6-090AAD203413Q33739398-E5901673-FAC7-4AFC-BC88-91C121D4A87CQ34700686-A14CFE1E-CB74-4888-82BD-70F36D38908CQ34945204-8DB4D34B-259C-4EA0-845C-BF2957B6BD0AQ35482538-D4C34803-D935-4B30-A75C-533FEEE1B2AFQ35999265-DD882C88-B221-485C-B2B3-840E4FD50C34Q36455737-3F99D535-8C67-4B3B-869F-664DC17639B8Q36604821-179E263B-3C0E-4F47-BE4C-96D96049510FQ36776108-51B29108-DC3C-4E61-A0BD-9FC498CEE549Q37167729-920EB5DA-B225-46FB-B3E9-231C999CC0CFQ37623579-63E2B8F2-B8FD-4C02-B7F9-518FB0808B74Q38156421-51F72DFC-A210-4533-9BF7-4B97271FA19EQ38192001-59A27A29-9CCF-468F-9250-E9AAE2D64A29Q38205451-300D9440-C772-44A0-B451-D6D9626B0C6FQ38225356-40847859-88C0-4249-AB09-1097A608DB98Q38511211-F83657F4-3A20-464D-8F2F-A18AD317D67DQ38671535-DE3399D5-F991-492D-BCF2-E8ADB8A325B3Q38797460-D85BC275-ABFE-40DB-892D-63E22CDDBA74Q38888515-EED536B8-3E2D-42E8-992F-602D671F0F67Q39273435-AC28C8BD-4F2D-4C61-85C0-6EC6DB999C72Q39471229-67031D99-3466-427E-9961-7A0E32DCE33FQ39549367-05691B8C-6C3A-4DF0-9DDC-BD220A14961CQ40385380-1D67980A-9894-4704-9391-9C4C7A863AD1Q41677439-B3A6ED2C-7244-418F-975F-6AAF4C1CD8D9Q41990822-C4A1F71F-8953-4574-B8F7-BD777B69087DQ42604807-81F058F4-A992-4D12-B942-963D2F868559Q45802306-EB2DBC81-7B9F-4B9D-92A2-FA8CEB00C817Q46250558-CC776E70-850F-44C9-8D51-2EE9F0292695Q47118269-70E2953E-8777-464D-BBC7-516FC9BB5256Q55236081-94F2AFFD-4A07-419C-B6BE-E9A1A2883C37Q55398190-E7851CDD-3B68-4D9B-BCAD-2C4937CDB9E9
P2860
Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Local or systemic treatment fo ...... risk of mucosal leishmaniasis.
@en
type
label
Local or systemic treatment fo ...... risk of mucosal leishmaniasis.
@en
prefLabel
Local or systemic treatment fo ...... risk of mucosal leishmaniasis.
@en
P2093
P2860
P50
P1433
P1476
Local or systemic treatment fo ...... risk of mucosal leishmaniasis.
@en
P2093
Eric Caumes
Gloria Morizot
Gundel Harms
Johannes Blum
Mark S Bailey
Pierre Buffet
Pieter P A M van Thiel
P2860
P304
P356
10.1016/J.INHE.2012.06.004
P577
2012-09-01T00:00:00Z